

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Beijing Chunlizhengda Medical Instruments Co., Ltd.**



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

ANNOUNCEMENT ON APPROVAL OF A SHARE OFFERING BY THE LISTING COMMITTEE FOR THE SSE STAR MARKET

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and the inside information provision under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) dated 3 November 2015, 22 April 2020, 5 June 2020, 22 December 2020, 22 June 2021, and 7 July 2021 in relation to, among others, the A Share Offering, the circulars of the Company’s 2020 second extraordinary general meeting, 2020 second Domestic Shareholders’ class meeting and 2020 second H Shareholders’ class meeting dated 24 July 2020 and the Company’s 2021 first extraordinary general meeting, 2021 first Domestic Shareholders’ class meeting and 2021 first H Shareholders’ class meeting dated 16 July 2021 (the “**Circulars**”), the announcement of the Company dated 10 August 2021 in relation to the poll results of the Company’s 2020 second extraordinary general meeting, 2020 second Domestic Shareholders’ class meeting and 2020 second H Shareholders’ class meeting and the announcement of the Company dated 10 August 2021 in relation to the poll results of the Company’s 2021 first extraordinary general meeting, 2021 first Domestic Shareholders’ class meeting and 2021 first H Shareholders’ class meeting dated 6 August 2021. Unless the context requires otherwise, terms and expressions used in this announcement shall have the same meanings as those defined in the aforementioned Circulars.

The Board of Directors hereby announces that the fifty-seventh review meeting for the year 2021 of the Listing Committee for Sci-tech Innovation Board of Shanghai Stock Exchange (the “SSE STAR Market”) was held on 19 August 2021. In accordance with the review results of the meeting, the A Share Offering on the SSE STAR Market of the Company has been approved.

As the A Share Offering is subject to approval by the CSRC and may or may not proceed, Shareholders and investors are reminded to exercise caution when dealing in the H Shares of the Company. The Company will make further announcements on any material updates and developments in relation to the A Share Offering in accordance with the Listing Rules and other applicable laws and regulations.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Chunbao
Chairman

Beijing, the PRC, 20 August 2021

As at the date of this announcement, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purpose only*